AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06685705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate and Bupivacaine 0.125%
Description: patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.
Study NCT06685705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and Neostigmine
Description: patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally
Study NCT06685705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl and bupivacaine
Description: patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.
Study NCT06619496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human-led fall prevention program
Description: Human-led evidence-based fall prevention programs include Matter of Balance, Tai Chi Moving for Better Balance, Walk with Ease, or Arthritis Exercise
Study NCT06619496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar-led fall prevention program
Description: The avatar-led fall prevention program consists of the Otago Exercise Program
Study NCT06624007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pediatric Nursing Excellence (PNE) model
Description: The intervention group will apply pediatric Nursing Excellence (PNE) model included 28 Likert-type questions to assess nurses' general excellence level regarding the care of children undergoing orthopedic surgeries grouped under five main categories including engagement, values, principles, care delivery and continuous improvement.
Study NCT05730582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parkland Diabetes Detection Program (PDDP) Screening Invitation
Description: The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days.
Study NCT05730582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parkland Diabetes Detection Program (PDDP) Screening Invitation
Description: The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days.
Study NCT05711186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Structured SDM
Description: The conversation between the heart team member and the patient will be structured according the adapted three-talk model for patients with symptomatic aortic stenosis and using the American College of Cardiology's decision aid for patients deciding between TAVR and SAVR
Study NCT05711186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care will include baseline visits without a structured SDM approach. Usual care includes at least one decision making talk with a heart team member discussing information about the disease, treatment options as well as benefits and risks of each procedure.
Study NCT05903053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Self-Regulation Intervention
Description: Participants enrolled in a separate protocol (UC Davis IRB ID#1077801) will be invited to participate upon meeting eligibility criteria. All participants will receive the intake and exit assessment battery, with the intake assessment battery being completed as part of IRBNet ID#1077801. A multiple baseline design across participants will be used with varying introduction of treatment elements for a subset of enrolled intervention participants. An intense intervention phase will follow the baseline phase in which 45-60 minute intervention sessions will occur two times per week for approximately 4-6 weeks for a total of 8 sessions. At the conclusion of the intense intervention phase, coaches will provide booster sessions once weekly for a month (4 sessions total).
Study NCT06366516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Methylation Test
Description: Participants who aged 25-65 years with high-risk HPV infection are recruited.To start with,cervical exfoliated cells are collected, coded (according to the actual enrollment sequence), and stored in the pathology department where methylation testing is performed.In addition,patients will underwent colposcopy and biopsy.~Patients are followed up by cytology, high-risk HPV and methylation tests at 6 and 12 months after enrollment.Cervical conization and hysterectomy will be taken if necessary according to histopathological results. The clinical endpoint is reached when CIN2+ is confirmed by histopathological result.
Study NCT05969119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
Study NCT06233916 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [14C] D-1553
Description: \[14C\] D-1553 (approximately 400 mg/80 μCi)
Study NCT05969119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
Study NCT05381077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Whole body MRI (ZTE sequence)
Study NCT05737797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical cytology during surgery.
Description: Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
Study NCT05794061 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological instruments
Description: Cognitive and behavioral tests and questionnaires
Study NCT06555796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluritamig
Description: IV infusion
Study NCT05991115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital to Home Transition (H2H)
Description: The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
Study NCT05702034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally.
Study NCT05001087 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Not applicable-Observational study
Study NCT05702034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally
Study NCT06408935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered IV and SC.
Study NCT05987735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BLAME-LESS
Description: The BLAME-LESS program was designed to educate about common defense responses that may occur during and after (sexual) violence. The main goal of the program is to reduce the feelings of shame and/or guilt related to these responses. The program was created in collaboration with licensed developmental and clinical psychologists with extensive psycho-trauma expertise, young adults who are experienced experts, visual artists, and web designers. The program is offered via a website and consists of three modules.
Study NCT05843643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets
Study NCT05843643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study NCT05528458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80Mg Tab
Description: Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection
Study NCT05295771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival Phenotype Modification
Description: Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
Study NCT05295771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival Phenotype Modification
Description: Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
Study NCT03712657 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS
Description: 1. preoperative pain control;~2. avoiding application of ureter;~3. avoiding application of gastric tube;~4. avoiding application of irrigation;~5. avoiding application of drainage;~6. early exercising postoperatively;~7. early oral feeding postoperatively;~8. early discharging.
Study NCT04912440 — intervention group
Intervention type: DEVICE
Intervention: MSE-ERCP
Description: No interventional study, MSE-ERCP performed within routine treatment, (approved indication of device)
Study NCT04709692 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: (+)-SJ000557733 (SJ733)
Description: Anti-Malarial
Study NCT06486597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Liquid meal
Study NCT04774575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biomarker-guided strategy
Description: Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed
Study NCT05530460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retinal imaging with low-cost OCT device
Description: Retinal imaging with low-cost OCT device
Study NCT05530460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retinal imaging with commercial OCT device
Description: retinal imaging with commercial OCT device
Study NCT05668000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bluetooth-connected monitoring devices and a feedback system
Description: AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system
Study NCT04807309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol Pill
Description: Danazol 200 mg orally twice a day
Study NCT05668000 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mobile application
Description: The mobile application provide only self-management interventions.
Study NCT05668000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The mobile application provide only self-management interventions.
Study NCT04807309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day
Study NCT04466761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monosaccharide Powder
Description: Monosaccharide powder dissolved in water.
Study NCT04466761 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo (cellulose powder).
Study NCT05036577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment.~Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
Study NCT05036577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.
Study NCT05036577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
Study NCT05036577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
Study NCT05778838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midodrine Oral Tablet
Description: Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.
Study NCT05778838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine Oral Tablet
Description: Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.
Study NCT05465538 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [11C]UCB-J PET
Description: Single PET scan using the radioligand \[11C\]UCB-J
Study NCT04791319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT04791319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT04791319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.
Study NCT04791319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.
Study NCT04791319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.
Study NCT04791319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab will be administered subcutaneously.
Study NCT06478433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Munatoril Aerosol Combo
Description: Munatoril® Aerosol Combo is a Medical Device that contains:~5 ml single-dose vials of sterile, 3% hypertonic, near-neutral pH bromine-iodine saline solution, based on Cervia integral sea salt, salso-bromo-iodine saline mother water from the Cervia Thermal Baths and hyaluronic acid with high molecular weight.~Lavonase® syringe with blue nebulizer valve (microsol), 10 ml, Medical Device for the administration of solutions in nebulized form within the nasal cavities and nasopharynx.
Study NCT06478433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iperclenny
Description: Hypertonic and Isotonic solution present on market in italy.
Study NCT04620733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg
Description: Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
Study NCT04620733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for double-blind period, for a duration of up to 12 months
Study NCT04620733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 5 mg
Description: If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
Study NCT04982211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Oral propranolol hydrochloride capsules, dosed per participant weight
Study NCT04982211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral propranolol hydrochloride capsules, dosed per participant weight
Study NCT04982211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules, dosed per participant weight
Study NCT04921592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper extremity stimulation
Description: transcutaneous stimulation of the upper extremities
Study NCT05854654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Air Leaks
Description: The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing an hermetic closure proximal to the balloon.~This setting will allow us to perform several different endoscopic and RAB procedures in emulated physiologic conditions to complete the study.
Study NCT05258656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention group will receive education about nutrition, resources, and specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
Study NCT05258656 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive specific instructions on promoting healthy development of their infant, including guidance regarding infant sleep, screen time, and building healthy relationships.
Study NCT04696185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 MG
Description: Dapagliflozin 10 mg (daily oral dose)
Study NCT06437197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Removal of the coronal pulp chamber in an adult teeth
Study NCT06437197 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Removal of the coronal pulp chamber in an adult teeth
Study NCT05562947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS With Ranibizumab (100 mg/mL)
Description: Participants randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 microliters (μL) of the 100-mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for participants randomized to the IVT arm. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed 24-week intervals.
Study NCT05562947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (10 mg/mL)
Description: Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44.
Study NCT06291883 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Kang Guan Recipe (Treat)
Description: Accurately weigh the Chinese medicinal herbs in the formula by weight, conduct the origin identification of the medicinal materials, and follow the scientific traditional Chinese medicine preparation process. After extraction, concentration, and granulation, package them in aluminum foil, with each package containing 6 grams of concentrated powder.
Study NCT06291883 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Kang Guan Recipe (Placebo)
Description: Use 3% Kang Guan Recipe concentrated powder, mix evenly with starch, and package in aluminum foil, with each package containing 6 grams of concentrated powder.